Tweet
<hr style="color: rgb(209, 209, 225);" size="1"> <!-- / icon and title --> <!-- message --> http://www.flutrackers.com/forum/sho...ed=1#post20715
1: Vaccine. 2006 Apr 12;24 Suppl 2:S2-56-7. Related Articles, Links
Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.
Bracci L, Canini I, Venditti M, Spada M, Puzelli S, Donatelli I, Belardelli F, Proietti E.
Department of Cellular Biology and Neurosciences, Istituto Superiore di Sanita, V. le Regina Elena 299, 00161 Rome, Italy.
Type I IFN is a cytokine family endowed with multiple biological activities. In recent years, type I IFN has been demonstrated to play a crucial role in innate immunity, in dendritic cell maturation/differentiation and in the priming of primary antibody responses, especially when administered i.m. with a purified influenza vaccine. Due to the increasing interest in mucosal vaccination especially for respiratory infections, we investigated two different IFN-adjuvanted immunization protocols against influenza. In the first one, anesthesized C3H/HeN mice were instilled intranasally with 50 microl of a commercially available influenza vaccine containing 5 mg of hemagglutinin (HA) and a partially purified preparation of mouse IFN-alphal. A single intranasal administration of IFN-adjuvanted vaccine resulted in a full protection of 100% of mice against virus challenge while vaccine alone was only partially effective (40%). From the analysis of the specific antibody response emerged that type I IFN induced a significant increase of antibody titers in all the Ig subclasses with particular effect on IgG2a and IgA. To mimic aerosol administration and to limit vaccine delivery strictly to nasal mucosa, a second method of intranasal vaccination was developed in which mice were left awake and their nostrils moistened along the day of treatment (every 10 min) with six mini-doses (8 microl each) of vaccine +/- IFN-I with dose and timing equivalent to previous immunization protocol. This vaccination schedule prevented mice from pulmonary damage and the concomintant use of type I IFN induced an efficient and long lasting both local and systemic immune response. These findings shed new light on the involvement of type I IFN in the early phases of the immune response and open new and practical perspectives in vaccine research.
PMID: 16823927 [PubMed - in process]
Display Show
1: Vaccine. 2006 Apr 12;24 Suppl 2:S2-56-7. Related Articles, Links
Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.
Bracci L, Canini I, Venditti M, Spada M, Puzelli S, Donatelli I, Belardelli F, Proietti E.
Department of Cellular Biology and Neurosciences, Istituto Superiore di Sanita, V. le Regina Elena 299, 00161 Rome, Italy.
Type I IFN is a cytokine family endowed with multiple biological activities. In recent years, type I IFN has been demonstrated to play a crucial role in innate immunity, in dendritic cell maturation/differentiation and in the priming of primary antibody responses, especially when administered i.m. with a purified influenza vaccine. Due to the increasing interest in mucosal vaccination especially for respiratory infections, we investigated two different IFN-adjuvanted immunization protocols against influenza. In the first one, anesthesized C3H/HeN mice were instilled intranasally with 50 microl of a commercially available influenza vaccine containing 5 mg of hemagglutinin (HA) and a partially purified preparation of mouse IFN-alphal. A single intranasal administration of IFN-adjuvanted vaccine resulted in a full protection of 100% of mice against virus challenge while vaccine alone was only partially effective (40%). From the analysis of the specific antibody response emerged that type I IFN induced a significant increase of antibody titers in all the Ig subclasses with particular effect on IgG2a and IgA. To mimic aerosol administration and to limit vaccine delivery strictly to nasal mucosa, a second method of intranasal vaccination was developed in which mice were left awake and their nostrils moistened along the day of treatment (every 10 min) with six mini-doses (8 microl each) of vaccine +/- IFN-I with dose and timing equivalent to previous immunization protocol. This vaccination schedule prevented mice from pulmonary damage and the concomintant use of type I IFN induced an efficient and long lasting both local and systemic immune response. These findings shed new light on the involvement of type I IFN in the early phases of the immune response and open new and practical perspectives in vaccine research.
PMID: 16823927 [PubMed - in process]
Display Show